Zepbound Global Regulatory Status

FDA Approval Timeline and Regulatory Pathway

The FDA granted Zepbound approval on November 8, 2023, through the standard New Drug Application pathway under NDA 217806 [1]. This approval came 18 months after the FDA first approved tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022. The obesity indication relied on a separate clinical dossier built around the SURMOUNT trial program.

Eli Lilly submitted the NDA in the first half of 2023, and the FDA designated the application for Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target date of November 2023 [1]. The agency's Endocrinologic and Metabolic Drugs Advisory Committee did not convene a formal advisory committee meeting before the approval decision. This is a regulatory pattern the FDA has used with other GLP-1 receptor agonists when the clinical dataset is considered sufficiently strong and the mechanism of action is well characterized.

Zepbound became the second anti-obesity medication in the GLP-1 receptor agonist class to receive FDA approval, following semaglutide 2.4 mg (Wegovy) in June 2021 [2]. The FDA approved Zepbound specifically for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [1].

The SURMOUNT Clinical Trial Program

Zepbound's approval rested on the SURMOUNT series of phase 3 trials, the largest of which was SURMOUNT-1 [3]. This 72-week, randomized, double-blind, placebo-controlled trial enrolled 2,539 adults with obesity or overweight with at least one weight-related comorbidity. None of the participants had type 2 diabetes.

The results were striking. Participants receiving tirzepatide 15 mg achieved a mean weight loss of 22.5% from baseline at 72 weeks, compared with 2.4% in the placebo group [3]. The 10 mg dose produced 21.4% mean weight loss, and the 5 mg dose produced 16.0% [3]. More than half of participants on the 10 mg and 15 mg doses lost at least 20% of their body weight. That threshold had previously been considered achievable only through bariatric surgery.

"These results represent a significant advance for obesity pharmacotherapy," stated Dr. Ania Jastreboff, the lead investigator on SURMOUNT-1 and Director of the Yale Obesity Research Center, in the published trial findings [3].

SURMOUNT-2 enrolled 938 adults with both obesity and type 2 diabetes [4]. At 72 weeks, tirzepatide 15 mg produced a mean weight loss of 14.7%, compared to 3.2% with placebo [4]. SURMOUNT-3 examined sequential therapy (intensive lifestyle intervention followed by tirzepatide) and SURMOUNT-4 evaluated the effects of treatment withdrawal. In SURMOUNT-4, participants who were switched from tirzepatide to placebo after 36 weeks regained approximately half of the weight they had lost, while those who continued tirzepatide maintained their weight loss through 88 weeks [5].

What the Zepbound Prescribing Label Says

The FDA-approved prescribing label for Zepbound contains several regulatory elements that prescribers must understand [6]. The label carries a boxed warning regarding thyroid C-cell tumors. In rodent studies, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). The clinical relevance of these findings in humans has not been determined.

Zepbound is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]. It is also contraindicated in patients with known serious hypersensitivity to tirzepatide or any of the excipients.

The dosing schedule follows a structured titration. Treatment starts at 2.5 mg once weekly for four weeks. That initial dose is not a therapeutic dose. It is intended to reduce gastrointestinal side effects during initiation. After four weeks, the dose increases to 5 mg once weekly. From there, increases of 2.5 mg may occur at minimum four-week intervals based on clinical response and tolerability, up to a maximum of 15 mg once weekly [6].

The label lists the following warnings and precautions: pancreatitis, gallbladder-related events, hypoglycemia when used with insulin or sulfonylureas, acute kidney injury (typically from dehydration due to gastrointestinal adverse reactions), hypersensitivity reactions, suicidal behavior and ideation, and diabetic retinopathy complications in patients with type 2 diabetes [6]. The FDA updated the label in 2024 to include more detailed language around suicidality monitoring following a post-market evaluation.

Gastrointestinal and Safety Profile in Clinical Trials

Gastrointestinal events were the most commonly reported adverse reactions across the SURMOUNT trial program [3][4]. In SURMOUNT-1, nausea occurred in 24.6% of participants on tirzepatide 5 mg, 33.3% on 10 mg, and 31.0% on 15 mg, compared with 9.5% on placebo [3]. Diarrhea rates ranged from 18.7% to 23.0% across tirzepatide doses versus 7.3% on placebo. Constipation occurred in 12.6% to 17.1% of tirzepatide-treated participants.

These events were predominantly mild to moderate in severity and occurred most frequently during the dose-escalation phase [3]. Discontinuation due to adverse events was 4.3% to 7.1% across tirzepatide groups compared with 2.6% for placebo.

Serious adverse events of clinical interest included cholelithiasis (gallstones), reported in 0.2% to 1.7% of tirzepatide groups versus 0.2% in placebo, and acute pancreatitis, which occurred in fewer than 0.2% of treated participants [3][4]. The FDA's post-market surveillance through the Sentinel system continues to monitor for signals related to thyroid cancer, pancreatitis, and gallbladder disease [7].

"Post-market surveillance is essential for GLP-1 receptor agonists and dual agonists given their widespread adoption," noted a 2024 FDA Drug Safety Communication [7]. The agency has not identified a causal link between tirzepatide and medullary thyroid carcinoma in humans, but active monitoring continues through the Sentinel system and the FDA Adverse Event Reporting System (FAERS).

Cardiovascular Outcomes and Ongoing Regulatory Submissions

Tirzepatide does not yet carry a cardiovascular risk reduction indication for Zepbound. The SURPASS-CVOT trial (now called SURMOUNT-MMO) is evaluating major adverse cardiovascular events in patients with obesity and established cardiovascular disease, with results expected in 2027 [8].

Interim cardiovascular safety data from the SURMOUNT program are encouraging. In pooled analyses of SURMOUNT-1 through SURMOUNT-4, tirzepatide was associated with reductions in systolic blood pressure of 6 to 9 mmHg and improvements in triglycerides, HDL cholesterol, and inflammatory markers including high-sensitivity C-reactive protein [3][4]. These cardiometabolic improvements mirror patterns seen with semaglutide before the SELECT trial confirmed cardiovascular benefit for that drug.

The FDA approved a supplemental indication for Zepbound in March 2025 for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, based on the SURMOUNT-OSA trial program [9]. In that trial, tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 55% to 63% at 52 weeks, compared with approximately 5% for placebo [9]. This made Zepbound the first pharmacologic therapy specifically approved for OSA.

European Medicines Agency and International Status

The European Medicines Agency (EMA) initially authorized tirzepatide under the brand name Mounjaro for type 2 diabetes in September 2022 [10]. The Committee for Medicinal Products for Human Use (CHMP) subsequently recommended expanding Mounjaro's indication to include chronic weight management, and the European Commission granted this extension in late 2024 [10].

Unlike in the United States, where tirzepatide is marketed under two separate brand names (Mounjaro for diabetes and Zepbound for obesity), the European regulatory framework uses a single brand. Mounjaro covers both indications across European Economic Area member states.

In Japan, tirzepatide received approval for type 2 diabetes as Mounjaro in 2022 through the Pharmaceuticals and Medical Devices Agency (PMDA). As of early 2026, an obesity indication has not yet been approved in Japan, though regulatory submissions are underway. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) authorized tirzepatide for both type 2 diabetes and weight management. The National Institute for Health and Care Excellence (NICE) issued a positive technology appraisal for tirzepatide for weight management in 2024, recommending its use within defined BMI criteria [11].

Australia's Therapeutic Goods Administration (TGA) approved tirzepatide for chronic weight management in 2024. Canada's regulatory review through Health Canada remains active, with approval anticipated in the near term. Across the Gulf Cooperation Council (GCC) states, the Saudi Food and Drug Authority (SFDA) and the UAE's Ministry of Health have approved tirzepatide for obesity management.

Supply, Distribution, and Shortage Considerations

Zepbound's launch in the United States coincided with widespread supply constraints affecting the entire incretin-based medication class [12]. The FDA placed tirzepatide injection products on its Drug Shortage Database beginning in late 2023 [12]. These shortages were driven by demand that exceeded Eli Lilly's manufacturing capacity, particularly for the 2.5 mg and 5 mg starter doses.

Eli Lilly invested over $18 billion in manufacturing expansion between 2023 and 2025, including new production facilities in Lebanon, Indiana; Research Triangle Park, North Carolina; and Limerick, Ireland [12]. The FDA removed tirzepatide from its shortage list in phases as supply normalized. This shortage had regulatory implications: during periods of declared shortage, compounding pharmacies produced copies of tirzepatide under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Once the FDA determined that the shortage had resolved, it issued guidance directing compounders to cease production, triggering litigation from compounding pharmacies and patient advocacy groups [13].

How Zepbound Compares Regulatorily to Other Anti-Obesity Drugs

Five prescription medications currently hold FDA approval specifically for chronic weight management: orlistat (Xenical, approved 1999), phentermine-topiramate ER (Qsymia, 2012), naltrexone-bupropion ER (Contrave, 2014), semaglutide 2.4 mg (Wegovy, 2021), and tirzepatide (Zepbound, 2023) [1][2]. Each carries distinct label restrictions and risk evaluation requirements.

Zepbound and Wegovy share the same boxed warning for thyroid C-cell tumors. Qsymia is available only through a Risk Evaluation and Mitigation Strategy (REMS) program due to teratogenicity concerns [14]. Zepbound does not require a REMS, but the label states that patients should discontinue tirzepatide at least two months before a planned pregnancy due to its long washout period [6].

From a weight-loss efficacy standpoint, tirzepatide's regulatory filings documented the highest placebo-adjusted weight loss of any FDA-approved anti-obesity medication. The 20.1 percentage-point difference between tirzepatide 15 mg and placebo in SURMOUNT-1 exceeded the 12.4 percentage-point difference between semaglutide 2.4 mg and placebo reported in the STEP-1 trial (N=1,961) [3][15]. Direct head-to-head data between Zepbound and Wegovy are expected from the ongoing SURMOUNT-5 trial.

Post-Market Regulatory Actions and Label Updates

Since the initial approval, the FDA has issued several post-market regulatory actions related to Zepbound [7]. In 2024, the FDA required Eli Lilly to add language to the Warnings and Precautions section addressing reports of ileus (intestinal obstruction), aligning with a class-wide update applied to all GLP-1 receptor agonists and dual GIP/GLP-1 agonists.

The European Pharmacovigilance Risk Assessment Committee (PRAC) conducted a review of GLP-1 receptor agonists, including tirzepatide, in 2024 following signal detection around suicidal ideation. The PRAC concluded that the available evidence did not support a causal association but recommended continued monitoring and updated product information to reflect the ongoing evaluation [10].

The FDA also addressed the compounding question through formal regulatory action. After determining that tirzepatide shortage had ended, the agency sent warning letters to compounding entities continuing to produce tirzepatide copies, asserting that such products were unapproved new drugs [13]. This regulatory enforcement action is still being litigated in federal courts as of mid-2026.